ISO 10993-3:2026 was officially published in August 2026 as the fourth edition of the standard. The updated standard addresses the biological evaluation of medical devices with respect to genotoxicity, carcinogenicity, reproductive toxicity, and developmental toxicity.
ISO 10993-3 provides manufacturers with strategies for evaluating these potential biological risks where they have been identified as relevant to the safety evaluation of a medical device. Rather than treating biological safety as a predefined testing exercise, the standard emphasizes a risk-based evaluation approach, taking into account factors such as the device’s intended use, duration and nature of exposure, and interactions with the human body.
The standard also supports the use of chemical characterization and toxicological risk assessment to determine whether additional biological testing is necessary and how identified hazards should be addressed. Where testing is considered appropriate, ISO 10993-3 provides relevant evaluation strategies and test methods.
This fourth edition represents a significant revision of the standard, with a greater emphasis on scientific evaluation and risk assessment rather than testing alone. It also incorporates genotoxicity test method guidance that was previously addressed in ISO/TR 10993-33.
Key Changes in ISO 10993-3:2026
- Risk-Based Framework: The revised standard reinforces the move away from rigid testing checklists towards an integrated biological risk assessment approach aligned with ISO 10993-1:2025.
- Genotoxicity and Extraction: The standard provides greater clarity on the use of exaggerated extraction in accordance with ISO 10993-12 for genotoxicity testing, alongside exhaustive extraction where appropriate and scientifically justified.
- Carcinogenicity Assessment: Greater emphasis is placed on chemical characterization and toxicological risk assessment to identify and manage potential carcinogenic hazards and reduce the need for animal testing where scientifically justified.
- Reproductive and Developmental Toxicity: The revised standard distinguishes more clearly between the evaluation of reproductive toxicity and developmental toxicity, taking into consideration factors such as exposure duration and the proximity of the device or its constituents to reproductive tissues.
Overall, ISO 10993-3:2026 strengthens the risk-based approach to biological evaluation and places greater emphasis on chemical characterization, toxicological assessment, scientific justification, and the reduction of unnecessary animal testing. Manufacturers should therefore consider the revised requirements when developing or updating their biological evaluation strategies and technical documentation.
The updated standard can be accessed using the following link
